Published in J Autoimmun on May 30, 2012
EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans. Glycobiology (2015) 0.88
Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol (2013) 0.88
Liquid-liquid diffusion crystallization improves the X-ray diffraction of EndoS, an endo-β-N-acetylglucosaminidase from Streptococcus pyogenes with activity on human IgG. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.83
Crystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodies. Proc Natl Acad Sci U S A (2014) 0.81
Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin Immunopathol (2014) 0.77
Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim Biophys Acta (2016) 0.76
Therapeutic potential of deglycosylated antibodies. Proc Natl Acad Sci U S A (2013) 0.76
EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils. PLoS One (2014) 0.75
Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood (2006) 2.49
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci Signal (2011) 1.95
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol (2008) 1.81
Coxsackievirus-adenovirus receptor (CAR) is essential for early embryonic cardiac development. J Cell Sci (2005) 1.79
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med (2002) 1.75
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Mitochondrial gene polymorphisms that protect mice from colitis. Gastroenterology (2013) 1.53
Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci (2011) 1.51
Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol (2007) 1.49
Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.48
Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. J Invest Dermatol (2013) 1.48
Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J Clin Invest (2005) 1.48
Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood (2009) 1.47
Pemphigoid diseases. Lancet (2012) 1.47
Inhibition of Rho A activity causes pemphigus skin blistering. J Cell Biol (2006) 1.45
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A (2008) 1.44
EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. Exp Dermatol (2014) 1.41
Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol (2014) 1.40
Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges (2009) 1.40
Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest (2005) 1.38
Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One (2008) 1.37
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer (2011) 1.30
Epidermolysis bullosa acquisita: what's new? J Dermatol (2010) 1.28
IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol (2010) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
IL-7-producing stromal cells are critical for lymph node remodeling. Blood (2012) 1.22
Shift of monocyte function toward cellular immunity during sleep. Arch Intern Med (2006) 1.22
Selective loss of cholinergic sudomotor fibers causes anhidrosis in Ross syndrome. Ann Neurol (2002) 1.18
Defining the quantitative limits of intravital two-photon lymphocyte tracking. Proc Natl Acad Sci U S A (2011) 1.17
Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction. J Immunol (2008) 1.17
Cysteine proteinase SpeB from Streptococcus pyogenes - a potent modifier of immunologically important host and bacterial proteins. Biol Chem (2011) 1.17
The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol (2007) 1.16
Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol (2009) 1.15
Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol (2007) 1.14
Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease. J Infect Dis (2004) 1.14
Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering. Nat Commun (2013) 1.14
Circadian clocks in mouse and human CD4+ T cells. PLoS One (2011) 1.13
Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus. J Biol Chem (2009) 1.13
Mechanisms of blister induction by autoantibodies. Exp Dermatol (2005) 1.12
Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges (2009) 1.11
The 21st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity. Exp Dermatol (2006) 1.11
Disorganization of the desmin cytoskeleton and mitochondrial dysfunction in plectin-related epidermolysis bullosa simplex with muscular dystrophy. J Neuropathol Exp Neurol (2002) 1.09
Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev (2010) 1.07
Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol (2002) 1.07
Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol (2012) 1.06
Heparin-induced skin lesions. Lancet (2012) 1.05
The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood (2010) 1.05
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol (2011) 1.04
Collagen VI is a subepithelial adhesive target for human respiratory tract pathogens. J Innate Immun (2009) 1.04
Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis (2012) 1.03
Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol (2006) 1.03
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev (2009) 1.03
EndoS from Streptococcus pyogenes is hydrolyzed by the cysteine proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity. BMC Microbiol (2008) 1.02
The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res (2007) 1.01
Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol (2002) 1.01
The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is antibacterial. Antimicrob Agents Chemother (2008) 1.01
CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol (2008) 1.01
Characterization and genome sequencing of two Propionibacterium acnes phages displaying pseudolysogeny. BMC Genomics (2011) 1.01
The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Curr Cancer Drug Targets (2011) 1.00
Pemphigus IgG causes skin splitting in the presence of both desmoglein 1 and desmoglein 3. Am J Pathol (2007) 1.00
Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2'-deoxyguanosine) in ex vivo human skin. J Pineal Res (2012) 1.00
Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol (2010) 1.00
Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant (2010) 1.00
Human peripheral gammadelta T cells possess regulatory potential. Immunology (2009) 0.99
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol (2010) 0.99
Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol (2006) 0.99
Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest (2013) 0.99
Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun (2008) 0.99
Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol (2002) 0.99
Current therapy of the pemphigus group. Clin Dermatol (2011) 0.98
The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interferon Cytokine Res (2008) 0.98
Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. Am J Pathol (2010) 0.97
Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol (2004) 0.96
Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol (2011) 0.96
Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem (2004) 0.95
Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol (2010) 0.95
The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int (2011) 0.94
IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med (2007) 0.94
Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol (2009) 0.94
Emerging treatments for pemphigoid diseases. Trends Mol Med (2013) 0.94
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells. Int J Oncol (2011) 0.94